The latest report by IMARC Group, titled “Sexually Transmitted Disease (STD) Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global sexually transmitted disease (STD) diagnostics market size reached US$ 98.71 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 135.94 Billion by 2028, exhibiting a growth rate (CAGR) of 5.39% during 2023-2028.
Sexually transmitted disease (STD) diagnostics involve using a range of scientific tools and techniques to identify, detect, and confirm the presence of STDs in individuals. It encompasses various methods, including polymerase chain reaction (PCR) tests, nucleic acid amplification tests (NAATs), enzyme-linked immunosorbent assays (ELISAs), point-of-care (PoC) devices, and self-testing kits. It plays a crucial role in detecting and screening a wide range of sexually transmitted diseases and infections, including genital herpes, chlamydia, gonorrhea, syphilis, pubic lice, trichomoniasis, acquired immune deficiency syndrome (AIDS), bacterial vaginosis, scabies, and chancroid. It relies on blood, urine, genital swabs, and fluid samples to detect STDs, which are analyzed for pathogens and markers associated with STDs. Some commonly diagnosed STDs through these techniques include gonorrhea, herpes, hepatitis B and C, human immunodeficiency virus (HIV), and human papillomavirus (HPV). It offers high efficiency and accuracy, enabling early diagnosis of infections, facilitating timely intervention, preventing future complications, and ultimately improving patient outcomes. By facilitating early detection, STD diagnostics allow prompt and accurate treatment, essential in preventing complications such as infertility and protecting unborn children from infections. At present, STD diagnostics is gaining immense traction among physicians across the globe as it provides valuable insights into the nature and causes of these diseases.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/sexually-transmitted-disease-diagnostics-market/requestsample
Sexually Transmitted Disease (STD) Diagnostics Market Trends and Drivers:
The global sexually transmitted disease (STD) diagnostics market is primarily driven by the rising prevalence of STDs due to the surging instances of unprotected sexual intercourse and drug abuse. Moreover, the increasing use of STD diagnostics to assess the severity of infections, prevent further transmission, and determine appropriate treatment options, thereby improving patient outcomes, is positively influencing the market growth. Apart from this, the rising awareness among the general population regarding the importance of early disease detection to mitigate potential complications, including cancer, congenital disabilities, and infertility, has catalyzed market growth. Additionally, the development of multiplex assays, enabling the simultaneous detection of multiple STD pathogens in a single test, reducing costs, saving time, and enhancing diagnostic accuracy, has accelerated the product adoption rate. Besides this, the introduction of self-testing kits empowers individuals to conveniently test for the presence of STDs in the privacy of their homes, while improving accessibility, patient comfort, and confidentiality, is propelling the market growth. Furthermore, several favorable initiatives by governments of numerous countries to educate the masses about STDs, promote timely disease diagnosis, and provide better access to high-quality treatment and testing facilities are contributing to the market growth. Other factors, including the rising healthcare expenditure, surging investments in advanced diagnostic tools, and the increasing emphasis on sexual health among individuals, are also anticipated to drive the market further.
Report Segmentation:
The report has segmented the market into the following categories:
Type Insights:
Chlamydia TestingSyphilis TestingGonorrhea TestingHerpes Simplex Virus TestingHuman Papilloma Virus TestingHuman Immunodeficiency Virus TestingChancroid TestingOthersDevice Type Insights:
Laboratory DevicesThermal Cycler – PCRLateral Flow ReadersFlow CytometersAbsorbance Microplate Reader – Enzyme Linked Immunosorbent Assay (ELISA)OthersPoint of Care (PoC) DevicesPhone Chips (Microfluidics + ICT)Portable/Bench Top/Rapid Diagnostic KitsEnd User Insights:
Laboratory TestingPoint of Care (PoC) TestingMarket Breakup by Region:
North America (United States, Canada)Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)Latin America (Brazil, Mexico, Others)Middle East and AfricaCompetitive Landscape with Key Player:
Abbott LaboratoriesBecton Dickinson and CompanyBioMérieux SABio-Rad Laboratories Inc.Cepheid (Danaher Corporation)F. Hoffmann-La Roche AGHologic Inc., Qiagen N.V.Quidel CorporationSiemens Healthineers AG (Siemens AG)Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 |United Kingdom: +44-753-713-2163
Sign in to leave a comment.